Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients

Wissam Georges El Hajj Moussa, Rebecca Georges Farhat, Joseph Claud Nehme, Marwan Antoun Sahyoun, Alexandre Raymond Schakal, Alexandre Edmond Jalkh, Mariana Pierre Abi Karam, Georges Georges Azar, Wissam Georges El Hajj Moussa, Rebecca Georges Farhat, Joseph Claud Nehme, Marwan Antoun Sahyoun, Alexandre Raymond Schakal, Alexandre Edmond Jalkh, Mariana Pierre Abi Karam, Georges Georges Azar

Abstract

Aim: The purpose of this study is to evaluate and compare the efficacy of 4 prostaglandin analogues (PGAs) and to determine the incidence of ocular surface disease in newly diagnosed, primary open-angle glaucoma (POAG) patients started on one of those 4 PGAs: bimatoprost (benzalkonium chloride, BAK, 0.3 mg/mL), latanoprost (BAK 0.2 mg/mL), travoprost (polyquad), and tafluprost (BAK-free).

Patients and methods: In this single-center, open-label trial, 32 patients newly diagnosed with POAG were randomly started on one of the four PGAs. All patients underwent a complete ophthalmological exam at presentation and at 1, 3, and 6 months of follow-up. Dry eye disease (DED) was assessed using the original Ocular Surface Disease Index (OSDI) questionnaire, in order to evaluate the impact of the drops on the quality of life of patients.

Results: The mean age was 60.06 years ± 11.76. All four drugs equally and significantly reduced the intraocular pressure (IOP) with respect to the baseline IOP. There was a trend for a slightly greater reduction of IOP with bimatoprost, but the difference was not found to be statistically significant when compared to other PGAs. OSDI scores were significantly superior for travoprost (10.68 ± 5.73) compared to the other three drugs (p < 0.05). Latanoprost caused the most significant eyelash growth and iris discoloration. Conjunctival hyperemia and superficial keratitis occurrence were similar in the four groups.

Conclusion: All prostaglandin analogues equally and significantly reduce the IOP in patients with POAG. According to the results of the OSDI score, latanoprost seems to be the least tolerated among the four drugs.

Figures

Figure 1
Figure 1
Mean IOP in POAG patients treated with different prostaglandins in monotherapy, at inclusion and at 1 month, 3 months, and 6 months of follow-up. The percentage of IOP reduction is written above each column. A p value <0.05 is marked by an asterisk. IOP: intraocular pressure; POAG: primary open-angle glaucoma.
Figure 2
Figure 2
Different OSDI scores of patients treated with different prostaglandins. The three dashed lines represent the three subscales analysed to obtain a final OSDI score: vision-related function, ocular symptoms, and environmental triggers. A p value <0.05 is marked by an asterisk. OSDI indicates ocular surface disease index; N, M, and M0 represent, respectively, normal, mild, and moderate eye disease as defined by both physician's assessment and a composite disease severity score; POAG: primary open-angle glaucoma.

References

    1. Quigley H. A., Broman A. T. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology. 2006;90(3):262–267. doi: 10.1136/bjo.2005.081224.
    1. Cristina Leske M., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Treatment Trial. Archives of Ophthalmology. 2003;121(1):48–56. doi: 10.1001/archopht.121.1.48.
    1. Lee A. J., McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clinical Ophthalmology. 2010;4:741–764. doi: 10.2147/OPTH.S10441.
    1. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Current Opinion in Ophthalmology. 1996;7(2):80–86. doi: 10.1097/00055735-199604000-00014.
    1. Vaede D., Baudouin C., Warnet J.-M., Brignole-Baudouin F. Preservatives in eye drops: toward awareness of their toxicity. Journal Français d'Ophtalmologie. 2010;33(7):505–524. doi: 10.1016/j.jfo.2010.06.018.
    1. Rossi G. C. M., Scudeller L., Rolle T., Pasinetti G. M., Bianchi P. E. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability. Expert Opinion on Drug Safety. 2015;14(5):619–623. doi: 10.1517/14740338.2015.1017467.
    1. Camras C. B., the United States Latanoprost Study Group Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103(1):138–147. doi: 10.1016/S0161-6420(96)30749-5.
    1. Fellman R. L., Kenneth Sullivan E., Ratliff M., et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002;109(5):998–1008. doi: 10.1016/S0161-6420(02)01010-2.
    1. Whitcup S. M., Cantor L. B., VanDenburgh A. M., Chen K. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. British Journal of Ophthalmology. 2003;87(1):57–62. doi: 10.1136/bjo.87.1.57.
    1. Chabi A., Varma R., Tsai J. C., et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. American Journal of Ophthalmology. 2012;153(6):1187–1196. doi: 10.1016/j.ajo.2011.11.008.
    1. Orzalesi N., Rossetti L., Bottoli A., Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113(2):239–246. doi: 10.1016/j.ophtha.2005.10.045.
    1. Alagöz G., Gürel K., Bayer A., Serin D., Çelebi S., Kükner Ş. A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica. 2008;222(2):88–95. doi: 10.1159/000112624.
    1. Chander A., Kapoor H., Thomas S. Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma. Nepalese Journal of Ophthalmology. 2013;5(1):75–80. doi: 10.3126/nepjoph.v5i1.7831.
    1. Schnober D., Hofmann G., Maier H., Scherzer M. L., Ogundele A. B., Jasek M. C. Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clinical Ophthalmology. 2010;4:1459–1463. doi: 10.2147/OPTH.S13720.
    1. Holmstrom S., Buchholz P., Walt J., Wickstrom J., Aagren M. Analytic review of Bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Current Medical Research and Opinion. 2005;21(11):1875–1883. doi: 10.1185/030079905X65600.
    1. Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. Journal of Glaucoma. 2008;17(8):667–673. doi: 10.1097/IJG.0b013e3181666557.
    1. Cheng J. W., Wei R. L. Meta-analysis of 13 randomized controlled trials comparing Bimatoprost with latanoprost in patients with elevated intraocular pressure. Clinical Therapeutics. 2008;30(4):622–632. doi: 10.1016/j.clinthera.2008.04.006.
    1. Denis P., Lafuma A., Khoshnood B., Mimaud V., Berdeaux G. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Current Medical Research and Opinion. 2007;23(3):601–608. doi: 10.1185/030079907X178720.
    1. Eyawo O., Nachega J., Lefebvre P., et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clinical Ophthalmology. 2009;3:447–456. doi: 10.2147/OPTH.S6501.
    1. Li N., Chen X. M., Zhou Y., Wei M. L., Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clinical & Experimental Ophthalmology. 2006;34(8):755–764. doi: 10.1111/j.1442-9071.2006.01237.x.
    1. Orme M., Collins S., Dakin H., Kelly S., Loftus J. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Current Medical Research and Opinion. 2010;26(3):511–528. doi: 10.1185/03007990903498786.
    1. Ranno S., Sacchi M., Brancato C., Gilardi D., Lembo A., Nucci P. A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients. Scientific World Journal. 2012;2012, article 804730:6. doi: 10.1100/2012/804730.
    1. Lin L., Zhao Y. J., Chew P. T. K., et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. The Annals of Pharmacotherapy. 2014;48(12):1585–1593. doi: 10.1177/1060028014548569.
    1. Hommer A., Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clinical Ophthalmology. 2011;5:623–631. doi: 10.2147/OPTH.S17876.
    1. Brasnu E., Brignole-Baudouin F., Riancho L., Guenoun J.-M., Warnet J.-M., Baudouin C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Current Eye Research. 2008;33(4):303–312. doi: 10.1080/02713680801971857.
    1. Liang H., Baudouin C., Pauly A., Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. The British Journal of Ophthalmology. 2008;92(9):1275–1282. doi: 10.1136/bjo.2008.138768.
    1. Kahook M. Y., Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Advances in Therapy. 2008;25(8):743–751. doi: 10.1007/s12325-008-0078-y.
    1. Kim J. H., Kim E. J., Kim Y. H., et al. In vivo effects of preservative-free and preserved prostaglandin analogs: mouse ocular surface study. Korean Journal of Ophthalmology. 2015;29(4):270–279. doi: 10.3341/kjo.2015.29.4.270.
    1. Wand M., Gilbert C. M., Liesegang T. J. Latanoprost and herpes simplex keratitis. American Journal of Ophthalmology. 1999;127(5):602–604. doi: 10.1016/S0002-9394(99)00050-1.
    1. Deai T., Fukuda M., Hibino T., Higaki S., Hayashi K., Shimomura Y. Herpes simplex virus genome quantification in two patients who developed herpetic epithelial keratitis during treatment with antiglaucoma medications. Cornea. 2004;23(2):125–128. doi: 10.1097/00003226-200403000-00004.
    1. Ekatomatosis P. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. The British Journal of Ophthalmology. 2001;85(8):1007a–11007. doi: 10.1136/bjo.85.8.1007a.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren